HEPION PHARMACEUTICALS, INC. Cash and Restricted Cash
HEPION PHARMACEUTICALS, INC. (HEPA) had Cash and Restricted Cash of $1.63 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.63M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.60M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.83M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.32M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.60M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.83M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $2.32M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.92M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $4.59M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $406.41K 10-Q · filed 2026-08-13 |
| 2024-09-30 | $1.50M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $2.12M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $13.11M 10-Q · filed 2025-05-19 |
| 2023-12-31 | $14.79M 10-K · filed 2026-03-12 |
| 2023-09-30 | $19.28M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $30.52M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $42.99M 10-Q · filed 2024-05-21 |
| 2022-12-31 | $51.19M 10-K · filed 2025-04-08 |
| 2022-09-30 | $59.15M 10-Q · filed 2023-11-20 |
| 2022-06-30 | $71.71M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $79.22M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $91.35M 10-K · filed 2024-04-16 |
| 2021-09-30 | $98.73M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $110.09M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $115.45M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $40.73M 10-K · filed 2023-04-10 |
| 2020-09-30 | $13.71M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $17.56M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $16.05M 10-Q · filed 2021-05-14 |
| 2019-12-31 | $13.92M 10-K · filed 2022-04-08 |
| 2019-09-30 | $14.86M 10-Q · filed 2020-11-16 |
| 2019-06-30 | $17.15M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $1.68M 10-Q · filed 2020-06-29 |
| 2018-12-31 | $2.83M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |